Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression.

@article{Oelze2013ChronicTW,
  title={Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression.},
  author={Matthias Oelze and Maike Knorr and Swenja Kr{\"o}ller-Sch{\"o}n and Sabine Kossmann and Anna Gottschlich and Robert R{\"u}mmler and Alexandra Schuff and Steffen Daub and Christopher Doppler and Hartmut Kleinert and Tommaso Gori and Andreas Daiber and Thomas F. M{\"u}nzel},
  journal={European heart journal},
  year={2013},
  volume={34 41},
  pages={3206-16}
}
AIMS Isosorbide-5-mononitrate (ISMN) is one of the most frequently used compounds in the treatment of coronary artery disease predominantly in the USA. However, ISMN was reported to induce endothelial dysfunction, which was corrected by vitamin C pointing to a crucial role of reactive oxygen species (ROS) in causing this phenomenon. We sought to elucidate… CONTINUE READING